The frequency of KRAS mutation (20/40 as assessed by the Amgen laboratory) in the tumor biopsy specimens used in this study is consistent with that previously observed in clinical studies investigating KRAS mutations in CRC [11,12]. The gene discussed is KRAS; the disease is neoplasm.